Cơn sốt cục bộ hay sự phục hồi hoàn toàn? Phân tích dữ liệu Solana Chain MEME Whale Movements và sự khác biệt của thị trường

YZY Bio

company

About

YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies.

  • Wuhan,Hubei,China
  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
¥250M
Industries
Biotechnology,Health Care,Pharmaceutical,Product Research
Founded date
Jul 1, 2010
Number Of Employee
51 - 100
Operating Status
Active
Legal Name
Wuhan YZY Biopharma Co., Ltd.
Also Known As
友芝友生物制药,Youzhiyou Biopharmaceuticals

YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies based on breakthrough discoveries in molecular biology, enabling patients with major diseases to obtain more efficient treatment solutions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
¥450M
YZY Bio has raised a total of ¥450M in funding over 2 rounds. Their latest funding was raised on Jul 4, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 4, 2022 Series C ¥200M Detail
Sep 13, 2021 Series B ¥250M 4 Detail

Investors

Number of Lead Investors
Number of Investors
4
YZY Bio is funded by 4 investors. TD Capital and Sanhua Hongdao Investment are the most recent investors.
Investor Name Lead Investor Funding Round
TD Capital Series B
Sanhua Hongdao Investment Series B
Wuhan Institute of Biotechnology Series B
BGI Co-Win Series B

Employee Profiles

Number of Employee Profiles
1
YZY Bio has 1 current employee profiles, including Executive Pengfei Zhou
Executive